What is the appropriate acute and long‑term management for a patient with heart failure with reduced ejection fraction (HFrEF) who presents with ventricular tachycardia (VT)?

Management of HFrEF with Ventricular Tachycardia

For a patient with HFrEF presenting with VT, immediate electrical cardioversion is required if hemodynamically unstable, followed by IV amiodarone or lidocaine for shock-refractory or recurrent VT, with subsequent ICD implantation for secondary prevention once stabilized (provided >1 year meaningful survival expected).

Acute Management

Hemodynamically Unstable VT

• Immediate direct current cardioversion is the first-line treatment 1, 2
• If conscious but hypotensive, provide immediate sedation before cardioversion
• For shock-refractory VT/VF (failure after 1-2 defibrillation attempts):
  • IV amiodarone: 300 mg IV push (150 mg if <45 kg), with additional 150 mg if needed 1
  • Alternative: IV lidocaine: 100 mg IV push (50 mg if <45 kg), with additional 50 mg if needed 1

Hemodynamically Stable Monomorphic VT

• Obtain 12-lead ECG for documentation 1
• Electrical cardioversion remains first-line even when stable 2
• If pharmacologic approach preferred:
  • IV amiodarone for patients with HF or suspected ischemia 2
  • IV procainamide or flecainide only if no severe HF or acute MI present 2

Electrical Storm (≥3 episodes in 24 hours)

• Non-selective beta-blocker (propranolol preferred) 1
• IV amiodarone 1
• Consider sedation/anesthesia 1
• Involve heart rhythm specialist early 1
• Treat acute heart failure if present 1

Critical Acute Evaluation

Before proceeding with long-term management, assess:

• Coronary angiography emergently if acute STEMI suspected 1
• Cardiac MRI if etiology unclear after initial evaluation 1
• Exclude acute ischemia, electrolyte abnormalities, drug toxicity 1

Long-Term Management

Secondary Prevention ICD

An ICD is mandatory (Class I recommendation) to reduce sudden death and all-cause mortality in patients who have recovered from hemodynamically unstable ventricular arrhythmia, provided they are expected to survive >1 year with good functional status 3. This is the highest level of evidence (Level A) for secondary prevention.

Critical timing consideration: Do not implant ICD within 40 days of MI, as implantation during this period does not improve prognosis 3.

Optimal Medical Therapy for HFrEF

Continue or optimize guideline-directed medical therapy, which reduces VT substrate:

1. ACE-I or ARNI (Class I, Level A) 3
2. Beta-blocker (Class I, Level A) - particularly important for VT prevention 3
3. Mineralocorticoid receptor antagonist (Class I, Level A) 3
4. SGLT2 inhibitor (based on contemporary evidence) 4
5. Diuretics if congestion present (Class I, Level B) 3

Antiarrhythmic Therapy

• Amiodarone is the preferred antiarrhythmic in HFrEF patients with recurrent VT 1, 2
• Other antiarrhythmics have negative inotropic effects and increase HF hospitalization risk
• Avoid diltiazem or verapamil - they worsen HF and increase hospitalization (Class III recommendation) 3

Catheter Ablation

• Consider urgent catheter ablation for electrical storm refractory to medical therapy 2
• Requires high degree of expertise and should be performed at experienced centers 5
• May reduce ICD shocks and improve quality of life 1

CRT Consideration

If patient meets criteria (LVEF ≤35%, QRS ≥130 msec with LBBB morphology, NYHA Class II-III despite optimal medical therapy):

• CRT-D (combined CRT and ICD) is recommended (Class I, Level A) 3
• Improves symptoms, reduces morbidity and mortality 3

Common Pitfalls to Avoid

1. Do not delay cardioversion in unstable patients to obtain IV access or administer medications
2. Do not use beta-blockers, sotalol, or propafenone acutely in patients with decompensated HF
3. Do not implant ICD in the immediate post-MI period (wait >40 days) 3
4. Do not use multiple antiarrhythmic drugs simultaneously - increases proarrhythmic risk 6
5. Do not forget to assess and correct reversible causes: ischemia, electrolytes, medications, thyroid function 1

Special Considerations

If polymorphic VT with prolonged QT (Torsades de Pointes):

• Remove/correct precipitant
• IV magnesium
• Overdrive pacing (atrial preferred)
• Non-selective beta-blocker
• IV lidocaine if refractory 1

If VT recurs despite ICD and medical therapy, escalate to catheter ablation or consider advanced HF therapies (LVAD, transplantation) in refractory cases 7, 8.

The evidence strongly supports this algorithmic approach, with the 2020 Canadian guidelines 1 and 2015 ESC guidelines 2 providing the most specific acute VT management protocols, while the 2016 ESC HF guidelines 3 provide the strongest evidence for ICD secondary prevention and optimal medical therapy.